Vascepa, a prescription omega-3 fatty acid, is effective in reducing heart disease risk. The medication reduces inflammation and has helped reduce major adverse cardiovascular events by 25% in patients with high triglycerides and established cardiovascular disease, according to the REDUCE-IT trial. Other studies also found Vascepa reduced the risk of cardiovascular events by 18%. The average cost of Vascepa is around $250 per month.
Rest, AustralianSuper Among Funds Hit By Cyberattack
Australia’s largest superannuation funds, including AustralianSuper, REST, Australian Retirement Trust, and Hostplus, have suffered from a coordinated cyber attack, with around 8,000 accounts breached. Hackers
